Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium
暂无分享,去创建一个
[1] A. Mellmann,et al. Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] H. Karch,et al. Molecular Profiling and Phenotype Analysis of Escherichia coli O26:H11 and O26:NM: Secular and Geographic Consistency of Enterohemorrhagic and Enteropathogenic Isolates , 2005, Journal of Clinical Microbiology.
[3] P. Tarr,et al. Shiga-toxin-producing and haemolytic uraemic syndrome , 2005 .
[4] R. Cherla,et al. Comparative evaluation of apoptosis induced by Shiga toxin 1 and/or lipopolysaccharides in human monocytic and macrophage-like cells. , 2005, Microbial pathogenesis.
[5] M. Menger,et al. Intravital fluorescence microscopy: a novel tool for the study of the interaction of Staphylococcus aureus with the microvascular endothelium in vivo. , 2005, The Journal of infectious diseases.
[6] F. Taieb,et al. Bacterial toxins that modulate host cell-cycle progression. , 2005, Current opinion in microbiology.
[7] H. Karch,et al. Cytolethal Distending Toxin from Shiga Toxin-Producing Escherichia coli O157 Causes Irreversible G2/M Arrest, Inhibition of Proliferation, and Death of Human Endothelial Cells , 2005, Infection and Immunity.
[8] A. Friedrich,et al. Transcriptional Analysis of Genes Encoding Shiga Toxin 2 and Its Variants in Escherichia coli , 2005, Applied and Environmental Microbiology.
[9] A. Friedrich,et al. A rapid method for the discrimination of genes encoding classical Shiga toxin (Stx) 1 and its variants, Stx1c and Stx1d, in Escherichia coli. , 2004, Molecular nutrition & food research.
[10] A. Macconnachie,et al. Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection , 2004, Current opinion in infectious diseases.
[11] A. Caprioli,et al. Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome , 2004, Cytometry. Part B, Clinical cytometry.
[12] P. Srimanote,et al. A New Family of Potent AB5 Cytotoxins Produced by Shiga Toxigenic Escherichia coli , 2004, The Journal of experimental medicine.
[13] K. Friedman,et al. Lepirudin prevents lethal effects of Shiga toxin in a canine model , 2004, Thrombosis and Haemostasis.
[14] V. L. Tesh,et al. Regulation of Proinflammatory Cytokine Expression by Shiga Toxin 1 and/or Lipopolysaccharides in the Human Monocytic Cell Line THP-1 , 2004, Infection and Immunity.
[15] D. Newburg,et al. Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells. , 2004, Microbial pathogenesis.
[16] H. Karch,et al. Phenotypic and Genotypic Analyses of Enterohemorrhagic Escherichia coli O145 Strains from Patients in Germany , 2004, Journal of Clinical Microbiology.
[17] H. Karch,et al. Characterization of Cytolethal Distending Toxin Genes and Expression in Shiga Toxin-Producing Escherichia coli Strains of Non-O157 Serogroups , 2004, Infection and Immunity.
[18] M. Karmali. Infection by shiga toxin-producing Escherichia coli , 2004, Molecular biotechnology.
[19] M. Karmali. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues. , 2004, The Journal of infectious diseases.
[20] H. Thysell,et al. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura , 1995, Pediatric Nephrology.
[21] T. Barratt,et al. The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome , 1989, Pediatric Nephrology.
[22] R. Cherla,et al. Shiga toxins and apoptosis. , 2003, FEMS microbiology letters.
[23] E. Hansen,et al. A CdtA-CdtC Complex Can Block Killing of HeLa Cells by Haemophilus ducreyi Cytolethal Distending Toxin , 2003, Infection and Immunity.
[24] S. McColl,et al. Enhanced CXC Chemokine Responses of Human Colonic Epithelial Cells to Locus of Enterocyte Effacement-Negative Shiga-Toxigenic Escherichia coli , 2003, Infection and Immunity.
[25] T. Uchida. STX-liposome conjugates as candidate vaccines. , 2003, Drugs of today.
[26] F. Gunzer,et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. , 2003, Blood.
[27] H. Karch,et al. Cytolethal Distending Toxin Gene Cluster in Enterohemorrhagic Escherichiacoli O157:H− and O157:H7: Characterization and Evolutionary Considerations , 2003, Infection and Immunity.
[28] A. Friedrich,et al. Shiga Toxin 1c-Producing Escherichia coli Strains: Phenotypic and Genetic Characterization and Association with Human Disease , 2003, Journal of Clinical Microbiology.
[29] C. Buchrieser,et al. Analysis of Genome Plasticity in Pathogenic and Commensal Escherichia coli Isolates by Use of DNA Arrays , 2003, Journal of bacteriology.
[30] C. Dehio. Recent progress in understanding Bartonella-induced vascular proliferation. , 2003, Current opinion in microbiology.
[31] C. Lingwood,et al. Induction by Sphingomyelinase of Shiga Toxin Receptor and Shiga Toxin 2 Sensitivity in Human Microvascular Endothelial Cells , 2003, Infection and Immunity.
[32] A. Edefonti,et al. Shiga Toxin–Producing Escherichia coli Infections Associated with Hemolytic Uremic Syndrome, Italy, 1988–2000 , 2003, Emerging infectious diseases.
[33] C. Lingwood. Shiga toxin receptor glycolipid binding. Pathology and utility. , 2003, Methods in molecular medicine.
[34] M. Bitzan,et al. Interaction of Shiga toxin with endothelial cells. , 2003, Methods in molecular medicine.
[35] D. Kohan,et al. Induction of apoptosis of human brain microvascular endothelial cells by shiga toxin 1. , 2003, The Journal of infectious diseases.
[36] W. Henderson,et al. Platelet-activating factor and Escherichia coli O157:H7 infections , 2002, Pediatric Nephrology.
[37] M. Kagnoff,et al. Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF‐κB and MAP kinase pathways and the upregulated expression of interleukin 8 , 2002, Cellular microbiology.
[38] G. Remuzzi,et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. , 2002, Kidney international.
[39] H. Karch,et al. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. , 2002, The Journal of infectious diseases.
[40] Tatsuo Yamamoto,et al. Enterohemolysin operon of Shiga toxin‐producing Escherichia coli: a virulence function of inflammatory cytokine production from human monocytes , 2002, FEBS letters.
[41] H. Karch,et al. Identification, Characterization, and Distribution of a Shiga Toxin 1 Gene Variant (stx1c) in Escherichia coli Strains Isolated from Humans , 2002, Journal of Clinical Microbiology.
[42] L. Barbieri,et al. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells 1 , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[43] P. Tarr. Basic fibroblast growth factor and Shiga toxin-O157:H7-associated hemolytic uremic syndrome. , 2002, Journal of the American Society of Nephrology : JASN.
[44] A. Friedrich,et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. , 2002, The Journal of infectious diseases.
[45] D. Acheson,et al. Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy , 2002, Pediatric Nephrology.
[46] T. Frisan,et al. The cytolethal distending toxins induce DNA damage and cell cycle arrest. , 2001, Toxicon : official journal of the International Society on Toxinology.
[47] D. Acheson,et al. Shiga Toxins Induce, Superinduce, and Stabilize a Variety of C-X-C Chemokine mRNAs in Intestinal Epithelial Cells, Resulting in Increased Chemokine Expression , 2001, Infection and Immunity.
[48] P. Murdoch,et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[49] D. Acheson,et al. Shiga Toxin Translocation across Intestinal Epithelial Cells Is Enhanced by Neutrophil Transmigration , 2001, Infection and Immunity.
[50] G. Remuzzi,et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. , 2001, Blood.
[51] E. Seidman,et al. Pathogenesis of Shiga Toxin-Associated Hemolytic Uremic Syndrome , 2001, Pediatric Research.
[52] E. Elliott,et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features , 2001, Archives of disease in childhood.
[53] J. Galán,et al. CdtA, CdtB, and CdtC Form a Tripartite Complex That Is Required for Cytolethal Distending Toxin Activity , 2001, Infection and Immunity.
[54] C. Dehio. Bartonella interactions with endothelial cells and erythrocytes. , 2001, Trends in microbiology.
[55] H. Karch,et al. Sorbitol-Fermenting Shiga Toxin-Producing Escherichia coli O157:H− Strains: Epidemiology, Phenotypic and Molecular Characteristics, and Microbiological Diagnosis , 2001, Journal of Clinical Microbiology.
[56] K. Nilsson,et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. , 2001, Blood.
[57] E. O'Loughlin,et al. Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells. , 2001, Microbes and infection.
[58] Craig S. Wong,et al. Von Willebrand Factor and Von Willebrand Factor-Cleaving Metalloprotease Activity in Escherichia coli O157:H7-Associated Hemolytic Uremic Syndrome , 2001, Pediatric Research.
[59] L. V. D. Heuvel,et al. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. , 2001, Journal of the American Society of Nephrology : JASN.
[60] J. H. Green,et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. , 2001, The Journal of infectious diseases.
[61] V. V. van Hinsbergh,et al. Verocytotoxin-induced apoptosis of human microvascular endothelial cells. , 2001, Journal of the American Society of Nephrology : JASN.
[62] K. Sandvig. Shiga toxins. , 2001, Toxicon : official journal of the International Society on Toxinology.
[63] J. Galán,et al. A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein. , 2000, Science.
[64] T. Higuchi,et al. Verotoxin-1 Induces Tissue Factor Expression in Human Umbilical Vein Endothelial Cells through Activation of NF-κB/Rel and AP-1 , 2000, Thrombosis and Haemostasis.
[65] C. Elwell,et al. DNase I homologous residues in CdtB are critical for cytolethal distending toxin‐mediated cell cycle arrest , 2000, Molecular microbiology.
[66] F. Proulx,et al. Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic‐uremic syndrome , 2000, The Pediatric infectious disease journal.
[67] Craig S. Wong,et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. , 2000, The New England journal of medicine.
[68] V. V. van Hinsbergh,et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. , 2000, Blood.
[69] E. Seidman,et al. Circulating levels of transforming growth factor-beta1 and lymphokines among children with hemolytic uremic syndrome. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[70] N. Koide,et al. Primary cultures of human endothelial cells are susceptible to low doses of Shiga toxins and undergo apoptosis. , 1999, The Journal of infectious diseases.
[71] M. Frosch,et al. Escherichia coli O157:H7 and O157:H−Strains That Do Not Produce Shiga Toxin: Phenotypic and Genetic Characterization of Isolates Associated with Diarrhea and Hemolytic-Uremic Syndrome , 1999, Journal of Clinical Microbiology.
[72] H. Kondo,et al. Inhibition of Neutrophil Apoptosis by Verotoxin 2 Derived from Escherichia coli O157:H7 , 1999, Infection and Immunity.
[73] D. Acheson,et al. Shiga Toxins Stimulate Secretion of Interleukin-8 from Intestinal Epithelial Cells , 1999, Infection and Immunity.
[74] J. Samuel,et al. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. , 1999, The Journal of infectious diseases.
[75] J. Lanser,et al. Molecular Characterization of a Shiga ToxigenicEscherichia coli O113:H21 Strain Lacking eaeResponsible for a Cluster of Cases of Hemolytic-Uremic Syndrome , 1999, Journal of Clinical Microbiology.
[76] A. Blann,et al. Markers of endothelial cell activation and injury in childhood haemolytic uraemic syndrome , 1999, Pediatric Nephrology.
[77] H. Karch,et al. Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections. , 1999, Diagnostic microbiology and infectious disease.
[78] J. Harlan,et al. HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Endothelial Cells Undergoing Apoptosis Become Proadhesive for Nonactivated Platelets , 1999 .
[79] Y. Ihara,et al. Localization of verotoxin receptors in nervous system , 1999, Brain Research.
[80] H. Miyata,et al. [Evaluation of thrombomodulin and tumor necrosis factor-alpha levels in patients with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection]. , 1999, Nihon Jinzo Gakkai shi.
[81] T. Pysher,et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. , 1999, The American journal of pathology.
[82] D. Acheson,et al. Responses of Human Intestinal Microvascular Endothelial Cells to Shiga Toxins 1 and 2 and Pathogenesis of Hemorrhagic Colitis , 1999, Infection and Immunity.
[83] S. McEwen,et al. Associations between Virulence Factors of Shiga Toxin-ProducingEscherichia coli and Disease in Humans , 1999, Journal of Clinical Microbiology.
[84] S. Lauwers,et al. Identification of New Verocytotoxin Type 2 Variant B-Subunit Genes in Human and Animal Escherichia coliIsolates , 1998, Journal of Clinical Microbiology.
[85] J. Vermylen,et al. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. , 1998, Kidney international.
[86] E. Seidman,et al. Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome. , 1998, The Pediatric infectious disease journal.
[87] P. Stricklett,et al. Shiga toxin-1 regulation of cytokine production by human proximal tubule cells. , 1998, Kidney international.
[88] H. Abboud,et al. Shiga toxin 1 elicits diverse biologic responses in mesangial cells. , 1998, Kidney international.
[89] U. Querfeld,et al. A 12-year-old boy with fatal hemolytic-uremic-syndrome, excessive neutrophilia and elevated endogenous granulocyte-colony-stimulating-factor serum concentrations. , 1998, Clinical nephrology.
[90] L. Monnens,et al. Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels in Urine and Serum of Patents with Hemolytic Uremic Syndrome , 1998, Pediatric Research.
[91] Yang Wang,et al. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. , 1998, The Journal of clinical investigation.
[92] G. Haycock,et al. Activation of Coagulation and Fibrinolysis in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome , 1997, Thrombosis and Haemostasis.
[93] D. Milford,et al. Delays in the diagnosis of oesophagogastric cancer: a consecutive case series , 1997, BMJ.
[94] D. Adu,et al. Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli infection , 1997, Archives of disease in childhood.
[95] M. Petric,et al. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits , 1997, Infection and immunity.
[96] B. Bell,et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. , 1997, Pediatrics.
[97] H. Karch,et al. EspP, a novel extracellular serine protease of enterohaemorrhagic Escherichia coli O157:H7 cleaves human coagulation factor V , 1997, Molecular microbiology.
[98] V. V. van Hinsbergh,et al. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. , 1997, Kidney international.
[99] R. Benz,et al. Pore-forming properties of the plasmid-encoded hemolysin of enterohemorrhagic Escherichia coli O157:H7. , 1996, European journal of biochemistry.
[100] T. Beattie,et al. The neutrophil oxidative burst in diarrhoea – associated haemolytic uraemic syndrome , 1996, Pediatric Nephrology.
[101] V. V. van Hinsbergh,et al. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. , 1996, Blood.
[102] D. Acheson,et al. Comparison of the effects of Shiga-like toxin 1 on cytokine- and butyrate-treated human umbilical and saphenous vein endothelial cells. , 1996, The Journal of infectious diseases.
[103] A. O’Brien,et al. Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice , 1996, Infection and immunity.
[104] G. Remuzzi,et al. Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. , 1995, Blood.
[105] T. Obrig,et al. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. , 1995, The Journal of infectious diseases.
[106] L. Beutin,et al. Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933 , 1995, Infection and immunity.
[107] V. V. van Hinsbergh,et al. Plasma cytokine levels in hemolytic uremic syndrome. , 1995, Nephron.
[108] J. Wells,et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. , 1994, JAMA.
[109] L. Monnens,et al. The Fibrinolytic System in the Hemolytic Uremic Syndrome: In Vivo and In Vitro Studies , 1994, Pediatric Research.
[110] C. Lingwood,et al. Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro , 1993, Infection and immunity.
[111] C. Lingwood,et al. Endothelial heterogeneity in Shiga toxin receptors and responses. , 1993, The Journal of biological chemistry.
[112] V. Jay,et al. Experimental verocytotoxemia in rabbits , 1992, Infection and immunity.
[113] T. Barratt,et al. Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. , 1992, Kidney international.
[114] N. Bang,et al. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome , 1992 .
[115] T. Obrig,et al. Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro , 1992, Infection and immunity.
[116] M. P. Jackson,et al. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. , 1992, Current topics in microbiology and immunology.
[117] M. McKee,et al. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511 , 1991, Infection and immunity.
[118] B. Rowe,et al. Changes in the postenteropathic form of the hemolytic uremic syndrome in children. , 1991, Clinical nephrology.
[119] J. Wells,et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. , 1990, The Journal of pediatrics.
[120] R. Petras,et al. Escherichia coli O157:H7-associated colitis. A clinical and histological study of 11 cases. , 1990, Gastroenterology.
[121] S. Ostroff,et al. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. , 1989, The Journal of infectious diseases.
[122] K. Forsyth,et al. NEUTROPHIL-MEDIATED ENDOTHELIAL INJURY IN HAEMOLYTIC URAEMIC SYNDROME , 1989, The Lancet.
[123] J. Brown,et al. Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1 , 1989, The Journal of cell biology.
[124] M. Karmali,et al. Infection by verocytotoxin-producing Escherichia coli , 1989, Clinical Microbiology Reviews.
[125] C. Lingwood,et al. Verotoxin receptor glycolipid in human renal tissue. , 1989, Nephron.
[126] M. P. Jackson,et al. Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine , 1988, Journal of bacteriology.
[127] L. Becker,et al. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. , 1988, Human pathology.
[128] J. Brown,et al. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells , 1988, Infection and immunity.
[129] T. Yutsudo,et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. , 1988, European journal of biochemistry.
[130] M. P. Jackson,et al. Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933 , 1987 .
[131] H. Lior,et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. , 1985, The Journal of infectious diseases.
[132] M. Petric,et al. SPORADIC CASES OF HAEMOLYTIC-URAEMIC SYNDROME ASSOCIATED WITH FAECAL CYTOTOXIN AND CYTOTOXIN-PRODUCING ESCHERICHIA COLI IN STOOLS , 1983, The Lancet.
[133] M. Kashgarian,et al. The importance of nonrenal involvement in hemolytic-uremic syndrome. , 1980, Pediatrics.
[134] G. Striker,et al. Renal microangiopathy of the hemolytic-uremic syndrome in childhood. , 1976, Nephron.